EORTC-BTG-1320临床试验中复发WHO 2级和3级脑膜瘤的3D体积生长率评估
本研究基于EORTC-BTG-1320随机II期试验,评估3D体积生长率(3DVGR)分类在复发WHO 2或3级脑膜瘤中的判别价值。纳入16例患者,结果显示3DVGR分类1或2的患者无进展生存期均超过6个月,且临床获益比例更高。作者认为3DVGR分类可能有助于在脑膜瘤临床试验中识别治疗活性的早期信号。
要点
- 3DVGR分类1或2与无进展生存期超过6个月相关。
- 3DVGR分类1和2合并的中位总生存期为34.7个月,分类3为7.2个月(P=0.061)。
- 分类1患者全部(2/2)、分类2患者75%(3/4)、分类3患者仅10%(1/10)获得临床获益。
核心结论
- 肿瘤3DVGR分类可能有助于在脑膜瘤临床试验中识别治疗活性的早期信号。
研究设计与样本
- 基于EORTC-BTG-1320随机II期临床试验的影像学分析,纳入至少有一次试验前可用MRI的患者。
- 共纳入16例患者,中位年龄58.5岁。
- 对连续MRI进行3D体积评估直至进展,2D影像反应由MRI改良Macdonald标准中心评估。
主要发现
- 最佳3DVGR分类为1类、2A类、3A类和3B类的患者分别有2例(16.7%)、4例(33.3%)、2例(16.7%)和4例(33.3%)。
- 所有无进展生存期超过6个月的患者最佳3DVGR分类均为1或2类。
- 3DVGR分类1和2合并的中位总生存期为34.7个月,分类3为7.2个月(P=0.061)。
- 分类1患者全部(2/2)、分类2患者75%(3/4)、分类3患者仅10%(1/10)获得临床获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported that tumor 3D volume growth rate (3DVGR) classification could help in the assessment of drug activity in patients with meningioma using 3 main classes and a total of 5 subclasses: class 1: decrease; 2: stabilization or severe slowdown; 3: progression. The EORTC-BTG-1320 clinical trial was a randomized phase II trial evaluating the efficacy of trabectedin for recurrent WHO 2 or 3 meningioma. Our objective was to evaluate the discriminative value of 3DVGR classification in the EORTC-BTG-1320. METHODS: All patients with at least 1 available MRI before trial inclusion were included. 3D volume was evaluated on consecutive MRI until progression. 2D imaging response was centrally assessed by MRI modified Macdonald criteria. Clinical benefit was defined as neurological or functional status improvement or steroid decrease or discontinuation. RESULTS: Sixteen patients with a median age of 58.5 years were included. Best 3DVGR classes were: 1, 2A, 3A, and 3B in 2 (16.7%), 4 (33.3%), 2 (16.7%), and 4 (33.3%) patients, respectively. All patients with progression-free survival longer than 6 months had best 3DVGR class 1 or 2. 3DVGR classes 1 and 2 (combined) had a median overall survival of 34.7 months versus 7.2 months for class 3 (P = .061). All class 1 patients (2/2), 75% of class 2 patients (3/4), and only 10% of class 3 patients (1/10) had clinical benefit. CONCLUSIONS: Tumor 3DVGR classification may be helpful to identify early signals of treatment activity in meningioma clinical trials.
引用
- Tabouret E, Furtner J, Graillon T, et al. 3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas. Neuro Oncol. 2024. PMID: 38452246. doi:10.1093/neuonc/noae037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。